Atay Oguzhan, the Chairman and CEO of BillionToOne, Inc., has made significant stock transactions as reported in a recent SEC filing. The filing, dated November 4, 2026, reveals multiple transactions involving the company's Class A Common Stock, which may indicate strategic adjustments in his ownership stake.

BillionToOne, Inc. operates in the medical laboratories sector, a field characterized by ongoing innovation and competition. The recent activity from Oguzhan highlights a trend among executives in the industry who are actively managing their equity positions.

Background

BillionToOne, Inc. is a company incorporated in Delaware and is classified under the SIC code for medical laboratories. The company is based in Menlo Park, California, at 1035 O'Brien Drive. The recent filing is part of a series of disclosures, with the latest being a Form 4 submitted to the SEC on November 4, 2026. Other recent filings include several Forms 144, indicating ongoing stock transactions.

What the Filing Says

The SEC filing reveals that Oguzhan engaged in multiple transactions on November 2, 2026. He acquired 16,667 shares at a price of $2.80 each and disposed of various amounts of shares at significantly higher prices, ranging from approximately $106.62 to $113.17. Following these transactions, Oguzhan's ownership of Class A Common Stock reflects a total of 443,629 shares.

Impact

This activity may affect shareholders and investors as it signals Oguzhan's confidence in the company's future prospects. Additionally, it reflects the broader trend within the medical laboratories industry, where executives are navigating market conditions and adjusting their holdings accordingly.

What's Next

The filing does not say what happens next.